STERIS (STE)
(Delayed Data from NYSE)
$236.01 USD
+1.87 (0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.01 USD
+1.87 (0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
Don't Overlook Steris (STE) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Steris' (STE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Steris (STE) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About Steris (STE) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's How STERIS (STE) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.
STERIS (STE) AST Business Expands, New Offerings Aid Growth
by Zacks Equity Research
STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
by Zacks Equity Research
STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Steris (STE) Up 2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Unlocking Steris (STE) International Revenues: Trends, Surprises, and Prospects
by Zacks Equity Research
Explore how Steris' (STE) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Steris (STE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Steris (STE) Matches Q4 Earnings Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
The Zacks Analyst Blog Highlights Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS
by Zacks Equity Research
Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS are included in this Analyst Blog.
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Reports for Micron Technology, Anheuser-Busch & Duke Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Micron Technology, Inc. (MU), Anheuser-Busch InBev SA/NV (BUD) and Duke Energy Corporation (DUK).
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.
Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?
by Zacks Equity Research
STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.
Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS
by Zacks Equity Research
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.